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In this study, we investigated the feasibility of incorporating protein drugs into electrospun fibrous 
mats (EFMs) for wound healing using lysozyme as a model drug. Lysozyme nanoparticles (Lyso- 
NPs) were first obtained by electrospray. Lysozyme solutions were prepared with a binary solvent 
mixture of ethanol (EtOH)-water (H2O) at varied volume ratios. Subsequently, Lyso-NPs were 
suspended in poly(lactic-co-glycolic acid) (PLGA) solutions using trifluoroethanol (TFE) as a solvent. 
Lyso-NPs loaded EFMs were obtained by electrospinning of the aforementioned suspensions, and the 
bioactivity of lysozyme in the EFMs was investigated using fluorescence-based assay kit. The 
electrosprayed Lyso-NPs were spherical with barely altered bioactivity as compared to the untreated 
raw material when using EtOH- H2O (30:70, v/v) as solvent. After the subsequent electrospinning 
process, more than 90 % of the bioactivity of lysozyme was retained compared to the raw material. 
The cytotoxicity of the produced EFMs was evaluated by thiazolyl blue tetrazolium bromide (MTT) 
study and the proliferation and distribution of mouse fibroblast cells (L929) growing on EFMs were 
investigated using 4,6-diamidino-2-phenylindol dihydrochloride (DAPI) for nucleic acid staining. 
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Nearly negligible cytotoxicity of all the EFMs was observed according to the MTT study. 
Furthermore, it was observed that the L929 cells grew well on the Lyso-EFMs, especially those with 
the modification of polyethylene glycol (PEG) that was added to improve the hydrophilicity of EFMs. 
This study demonstrated that the electrospray/electrospinning processes are suitable for loading 
biomacromolecules to produce functionalized wound dressings to promote wound healing. 
 




Wound dressings are expected to provide physical barriers to protect the wound area. Moreover, these 
should also mimic the extracellular matrix (ECM) providing adequate mechanical and structure 
support for cell attachment, proliferation and differentiation and thus, promoting the healing process 
of deep wounds and ulcers (1-4). In the recent years, wound dressings functionalized with 
biomacromolecules have been extensively investigated for wound healing. It has been reported that 
by formulating biomacromolecules, such as growth factors, into the dressing materials, wound 
healing could be promoted (5-7). The biological signals can actively guide and direct cell 
functions(5, 8, 9), however, the growth factors are usually unstable in vivo and can diffuse rapidly 
out from the target site due to exudates secretion around the wound area (10, 11). Therefore, the 
injection of growth factors directly to the wound site is ineffective due to their short half-life. In 
order to reach high efficiency of biological effects of growth factors, a functionalized wound 
dressing with a controlled drug release profile is needed to promote wound healing. 
 
Currently, electrospun fibrous mats (EFMs) are normally employed to deliver biomacromolecules 
locally to the target wound area (6, 12-14). For successful application of a drug delivery system loaded 
with biomacromolecules, two critical aspects need to be taken into account; the stability of the 
incorporated biomacromolecules and the release profile. The biomacromolecules can be protected 
from chemical, physical or enzymatic degradation processes after being incorporated into the release 
carriers (15). However, the bioactivity of the biomacromolecules might be lost due to the denaturation 
and deactivation during the formulating and manufacturing processes (16, 17). Besides these 
procedures, the stability of biomacromolecules within the EFMs during storage and in vivo release 
should also be taken into consideration (18, 19). 
 
So far, various strategies such as physical adsorption (20), blend electrospinning and co-axial 
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electrospinning (21-24) and covalent immobilization on the surface of EFMs (25-27) have been 
developed to prepare functionalized EFMs with biomacromolecules. The method using physical 
adsorption is the easiest way and the bioactivity of biomacromolecules can be well preserved, 
although the applications are limited due to uncontrolled release profiles (28). Controlled release of 
biomacromolecules can be achieved by blend electrospinning or co-axial electrospinning. Normally, 
suspensions or emulsions are prepared prior to the fabricating process, where aqueous solutions of 
biomacromolecules are suspended or emulsified in polymer solutions made of an organic solvent. In 
a co-axial electrospinning process, a solution of biomacromolecules and a solution of polymers are 
electrospun from different feeding channels. As frequently reported, the challenge for both blend 
electrospinning and co-axial electrospinning is to maintain the bioactivity of the biomacromolecules 
(16, 29). A previous study showed that the bioactivity of alkaline phosphatase decreased dramatically 
after either blend electrospinning or co-axial electrospinning, and less than 50 % of the bioactivity 
remained as compared to the untreated raw material (16). The bioactivity of biomacromolecules is 
also a problem for covalent immobilization, where it might be affected by the process of covalent 
conjugation, and also inactivated after exposing in the harsh environment in vivo (30). 
 
In this study, lysozyme was used as a  model protein drug because it is easy to obtain and the 
analytical methods to characterize its stability have been well reported in literature (31, 32). PLGA 
is a safe material which has been approved by FDA and widely used in pharmaceutical application 
with controllable drug release behavior. It was used as the EFMs forming material in this study 
because its application in the field of wound dressing has recently attracted more and more attention 
(33, 34). However, its potential in the wound healing application has far been fully investigated. As 
for PEG, it was selected because it is hydrophilic, and it was reported that PEG could stabilize 
protein structure and protect lysozyme from denaturation while using organic solvent in the EFMs 
fabrication process (16). In addition, it was reported that the release behaviors of lysozyme can be 
modified as improving the hydrophilicity of EFMs (23, 33). Herein, fabrication of lysozyme loaded 
EFMs with a focus on the bioactivity of lysozyme after electrospray/electrospinning and the 
chemical stability of lysozyme during the release study were evaluated in this study.  
 
2. Materials and Methods 
2.1 Materials 
 
PLGA (LA: GA, 50:50, molar ratio) with inherent viscosity (25°C, 0.1 % chloroform [CHL]) in the 
range of 0.61-0.74 dl/g was purchased from Evonik (Darmstadt, Germany). Lysozyme (from 
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chicken egg white), molecular biology grade of trifluoroethanol (TFE), ethanol (EtOH), acetonitrile, 
trifluoroacetic acid (TFA), Tween-20, molecular biology grade of paraformaldehyde, 4,6-
Diamidino-2-phenylindole dihydrochloride (DAPI), Triton-X100, poly(ethylene oxide) (PEG Mw 
20,000), thiazolyl blue tetrazolium bromide (MTT) and phosphate buffered saline (PBS) tablets 
were all obtained from Sigma-Aldrich (Brøndby, Denmark). Mouse fibroblast cell (L929) was 
acquired from ATCC (Wesel, Germany), and the cell culture medium Dulbecco’s Modified Eagle’s 
Medium (DMEM) and penicillin-streptomycin (PS) were obtained from Sigma-Aldrich (Brøndby, 
Denmark). Fetal bovine serum (FBS) was acquired from Biowest (MO, USA). All materials were 
used as obtained. 
 
2.2 Preparation of EFMs 
 
The molecular weight of PLGA used in this study was measured using a size exclusion 
chromatography, which has been reported in a previous study, i.e. Mw 67,900 kDa. (35). The 
PLGA was dissolved in TFE at a concentration of 30 % (w/v). The electrospinning setup included a 
syringe pump (Harvard Apparatus, Holliston, MA, USA) and a high-voltage supply (maximum of 
20kV, PS/FC20R06, Glassman High Voltage Inc., High Bridge, NJ, USA). The samples were 
collected on a rotating drum with the speed of 500 rpm/min at room temperature (RT) and ambient 
humidity. A 16 gauge needle (inner diameter 1.19 mm and outer diameter 1.65 mm) and 10 μL/min 
flow rate were used, and the distance between the nozzle tip to the grounded collector was 10 cm. 
The voltage was adjusted to get a stable cone-jet with a minimum change of approximately 9 kV. 
 
2.3 Preparation of lysozyme loaded EFMs 
 
2 % (w/v) lysozyme was dissolved in a binary solvent mixture of EtOH-H2O at different volume 
ratios of 20:80, 30:70, 40:60, or 80:20 (EtOH:H2O, v/v). Lyso- NPs were prepared by electrospray 
using the same setup as for preparing EFMs described in section 2.2. A 27 gauge needle (Chip Quik 
Inc., Niagara Falls, NY, USA) was used. The flow rate was 3 µL/min, and the distance between the 
nozzle tip to grounded collector was 4 cm. The electrosprayed Lyso-NPs were  collected and dried in 
a vacuum oven overnight. Lyso-NPs were dispersed into the PLGA polymer solutions and mixed 
well at varied mass ratios (i.e. 1:100, 2.5:100 or 5:100, Lyso: PLGA, w/w) before electrospinning. 
PEG was added together with Lyso-NPs to modify the lysozyme release behavior at varied mass 
ratios, i.e. 1:100, 5:100, 10:100, and 20:100 (PEG: PLGA, w/w). All the processing parameters for 




2.4 Biological activity of the incorporated lysozyme in EFMs 
 
The bioactivity of Lyso-NPs prepared by electrospray was evaluated using a fluorescence-based 
EnzChek® Lysozyme Assay Kit (Molecular Probes, Eugene, OR, USA). Evaluation of the bioactivity 
of Lyso-NPs prepared from different formulations was used to find the formulation with the best 
biological activity, which will be used for further electrospinning. In order to evaluate the 
bioactivity of Lyso-NPs after being electrospun, the samples were prepared under the same 
conditions as aforementioned in section 2.2, except that no PLGA polymer was added in the 
electrospinning solutions. In this study, the collected beads (not fibers) (ES-(Lyso-NPs)) were dried 
in a vacuum oven and then dissolved in H2O to evaluate its biological activity using the Lysozyme 
Assay Kit. Freshly dissolved lysozyme (raw material) served as a control for 100 % bioactivity. 
 
2.5 Morphology of EFMs 
The morphology of the prepared EFMs was characterized using scanning electron microscope (SEM, 
Hitachi High-Tech HITACHI, Tokyo, Japan). The samples were mounted on metal stubs with double- 
sided adhesive tape and coated under vacuum with gold in an argon atmosphere prior to observation. 
The specimens were then imaged at an accelerating voltage of 5 kV. 
 
2.6 Water contact angle (WCA) of the EFMs 
 
For evaluation of the hydrophilicity of the obtained EFMs, WCAs were measured using pendant drop 
analyzer (KRÜSS GmbH, Hamburg, Germany). A drop of water (20 µL) was added on the surface 
of the EFMs, and measurements were acquired at 0, 30 min, and 1 h to observe the change of WCA 
over time. Each specimen was measured in triplicate. 
 
2.7 Mechanical property 
 
The mechanical properties of the resulted EFMs were carried out using dynamic mechanical analysis 
instrument (DMA Q800, TA instruments, New Castle, DE, USA). All the samples were cut into a 
specific rectangular shape, with a width fixed at 2 mm cut by the tools provided by TA instruments 
and the length (approximately 1 cm) of the EFMs was detected by the DMA instrument software 
(DMA Q800). The thickness of the mats was exactly measured by the electronic micrometer (Schut 
Geometrical Metrology, Netherland). The mechanical properties of the EFMs were studied at RT 





2.8 In vitro release of lysozyme from EFMs 
 
The Lyso-EFMs were cut into small squares (2 x 2 cm) for the in vitro release study. The release 
study was performed in TPBS medium (0.1 v/v % Tween-20 in 0.01M PBS at pH 7.4) in 2.0 mL 
Eppendorf tube. Samples were incubated in a water bath with a shaking speed of 100 rpm either at 
37 ºC or at RT. Initially, 1 mL of TPBS was added to immerse the fibrous mats, and subsequently, 
200 µL medium was taken out at designated time intervals (0.5, 1, 2, 4, and 24 h) and 200 µL fresh 
TPBS was added to maintain the volume. Thereafter, at 2, 4 and 7 days, and similarly every week 
until 56 days, a sample was taken out and the release medium was replaced with 1 mL fresh TPBS 
medium. The Eppendorf tube was sealed with parafilm to prevent the evaporation of the release 
medium during the release study. 
The lysozyme concentration in the collected supernatant was analyzed by high performance liquid 
chromatography (HPLC) (1260 Infinity, Agilent Technologies, Santa Clara, CA, USA) using a 
reversed phase C18 column (300A, Phenomenex Aps, Værløse, Denmark) at 280 nm. The mobile 
phases consisted of phase A: acetonitrile/0.1 % (v/v) TFA and phase B: H2O/0.1 % (v/v) TFA. The 
gradient elution started from 32 % (v/v) of phase A to 60 % (v/v) of phase A over 10 min and return 
to the starting phase ratio within further 5 min at a flow rate of 1 mL/min. The release study was 
performed in triplicate, and the results were presented as cumulative release as a function of time. 
 
2.9 Chemical analysis of remained lysozyme in EFMs after release study 
 
At the end of release study, lysozyme residue inside EFMs was characterized using a previously 
reported method (36). Briefly, Lyso-EFMs was dissolved in TFE and centrifuged. Polymer solution 
was removed and the precipitated protein pellet was washed with TFE for 2 times. The protein 
pallet was reconstituted in 1mL TPBS at 37°C for 1 h to determine the soluble residue in EFMs. 
Any remaining precipitate was reconstituted in 1mL denaturing solution (TPBS/6M urea/ 1 mM 
EDTA) and incubated at 37°C for 30 min to determine the content of any physical aggregate. If any 
insoluble precipitate collected after previous treatment, it will be incubated with reducing solution 
(TPBS/6M urea/ 1 mM EDTA+ 10mM DL-dithiothereitol) to determine any disulfide-bonded 
aggregate. 
 
2.10 Cytotoxicity of the EFMs  
 
For investigating the cytotoxicity of the fabricated EFMs, the cell viability was measured using a 
MTT assay. Firstly, L929 cells were seeded in 96-well plates at 37 ˚C and 5 % CO2 overnight at a 
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density of 1 × 104 cells per well. EFMs were sterilized overnight using UV light followed by 
incubation with the pre-seeded cells. After incubation for 48 h, the EFMs were removed from the 
wells, and 10 µL MTT solution (5 mg/mL) was added to each well and incubated for 4 h at 37 ˚C 
and 5 % CO2. After 4 h, the supernatant was discarded, and 150 μL DMSO was added to terminate 
the reaction. The absorbance of the resultant solution was measured at 490 nm on a microplate 
reader (Varioskan LUX Multimode, Thermo Fisher Scientific, MA, USA). The cell viability was 
plotted as percentage of the optical density (OD) value for the control group (cells growing without 
addition of EFMs). The study was performed in triplicate 
 
2.11 Cell growth on EFMs  
 
For investigating the cell growth on the Lyso-EFMs, mouse fibroblast cells (L929) were utilized. 
EFMs (0.8 cm × 0.8 cm) were sterilized using UV light overnight before adding the EFMs to a 48- 
well plate followed by adding L929 cells in a seeding density of 1× 105 cells per well in 1 mL of 
culture medium. After incubation of the cells together with the EFMs for 48 h at 37 ˚C and 5 % CO2, 
the EFMs were washed three times with PBS, and then fixed with 4 v/v% paraformaldehyde in PBS 
for 20 min. 
 
For observing the morphology of cells growing on EFMs, the samples were dried after the fixing step 
followed by gold coating and visualization using SEM. For monitoring cell growth, DAPI was used 
for staining the cell nuclear. After the fixing step, 0.1 % Triton-X 100 in PBS was added for 5 min at 
RT for cell permeabilization, and then 1 % fetal bovine serum (FBS) was used for 20 min to reduce 
nonspecific background staining. Subsequently, the cells were stained with DAPI (10 µg/mL in PBS) 
for 5 min. Before each step and after the staining, the cells were washed gently three times with PBS. 
The stained samples were observed using fluorescence microscope (CellSens, Olympus America Inc., 
Center Valley, PA, USA). 
 
2.12 Statistical Analysis 
 
All the data are presented as mean ± standard deviation (SD). Where appropriate, statistical 
differences are evaluated with t-test using Origin software (v9.1, academic, OriginLab, Northampton, 
MA, USA). P-values below 5% (p < 0.05) are considered statistically significant. 
3. Results and Discussion 




Spherical Lyso-NPs were obtained using electrospray (Fig. 1), and it was found that the particle 
appearance was influenced by the solvent selection (binary mixtures of EtOH-H2O). The most 
homogenous particles (approximately 100 nm) were electrosprayed from a lysozyme solution using 
EtOH-H2O (20:80, v/v) as solvent (Fig. 1A). With an increase in EtOH amount in the binary solvent 
mixture, the particle appearance became multi-dispersed with large particles (approximately 100 ~ 
400 nm) (Fig. 1B-C), and with 80 % (v/v) EtOH, large particles and small fragments were obtained 
(Fig. 1D). This size difference might be due to the difference in conductivity of EtOH and H2O. 
Fewer charges accumulated on the particle surface when the amount of EtOH increased in the 
binary solvent mixture due to its reduced polarity as compared to H2O. . It is known that high 
coulomb repulsive force was generated because of the charges accumulated on the droplet surface 
(37). Coulomb repulsion force drives the droplets to break into smaller droplets and thereby, 
resulting in reduced particle size (38). Therefore, with increasing EtOH in the binary solvent, less 
Coulomb repulsion was generated; hence, part of the droplets could not break up into smaller 
droplets before collection. Furthermore, the drying of the droplets became faster with an increase in 
the proportion of ethanol in the binary solvent mixture. As a result, these droplets were solidified 
quicker than that containing more water, which prevented them to break up into smaller droplets.  
Uniform fibrous mats were obtained for all the EFMs prepared using electrospinning in this study 
(Supplementary Fig. S1). There was no difference between the EFMs with/without the modification 
of lysozyme and/or PEG. With an increase in the amount of Lyso-NPs in PLGA suspension (> 
5:100, Lyso:PLGA, w/w), unstable cone-jet started to present in the electrospinning process. 






Fig. 1 SEM images of electrosprayed Lyso-NPs from binary solvents with different ratios of EtOH 
and H2O. A: 20:80 (v/v) EtOH-H2O; B: 30:70 (v/v) EtOH- H2O; C: 40:60 (v/v) EtOH- H2O; D: 80:20 
(v/v) EtOH- H2O. 
 
3.2 Biological activity of lysozyme after electrospray and electrospinning  
 
The bioactivity of lysozyme was investigated for the electrosprayed Lyso-NPs. It was found that the 
bioactivity reduced with increasing EtOH in the binary solvent when comparing to lysozyme raw 
material (Fig. 2A). It might be due to that lysozyme began to aggregate with increasing EtOH in the 
binary solvent and thereby, the bioactivity was reduced (39, 40). However, the bioactivity of the 
Lyso-NPs prepared from EtOH-H2O (20:80, v/v) decreased more compared with the samples 
prepared from EtOH-H2O 30:70 and 40:60 (v/v), with a value of 78.6 ± 7.5%. It has been reported 
that the charges accumulated on the surface of droplets in the electrospray process could alter 
protein structure conformation (17). Corresponding to the SEM results, using EtOH-H2O (20:80, 
v/v) as solvent, the obtained Lyso-NPs had the largest surface area compared to other samples. In 
addition, due to the higher conductivity of H2O compared to EtOH, more charges could be generated 
on the surface of droplets when using EtOH-H2O (20:80, v/v) as solvent. Therefore, there is a high 
risk of structure deformation of the lysozyme in the Lyso-NPs prepared from EtOH-H2O (20:80, 
v/v). In this study, the bioactivity of Lyso-NPs prepared from EtOH-H2O (30:70, v/v) solution was 
100.5 ± 6.9 % compared to the untreated lysozyme raw material, which was selected for the 
following electrospinning study. 
It has previously been reported that using organic solvents to extract protein from hydrophobic 
polymer carriers to evaluate their bioactivity had a disadvantage of severely destroying protein 
bioactivity (29, 41). In order to study the bioactivity of Lyso-NPs after being electrospun, Lyso-
NPs were electrosprayed again under the same conditions as preparing EFMs excluding PLGA. As 
shown in Fig. 2B, the bioactivity of Lyso-NPs retained well after further electrospray (mimicking 
the electrospinning process). There was no statistical difference (p-value of 0.7, 0.1 and 0.4, 
respectively) for Lyso-NPs and the further electrosprayed-(Lyso-NPs) (ES-(Lyso-NPs)) with and 
without addition of PEG compared to untreated lysozyme raw material. It suggested that 
electrospray/electrospinning techniques could be used to incorporate biomacromolecules into 




Fig. 2 Bioactivity of electrosprayed or electrospun lysozyme. A: Bioactivity of Lyso- NPs from the 
binary solvent EtOH-H2O at varied volume ratios. “Lyso” refers to lysozyme raw material; “20EtOH” 
refers to Lyso-NPs prepared from EtOH-H2O (20:80, EtOH:H2O, v/v); B: Bioactivity of Lyso-NPs 
and electrosprayed-(Lyso-NPs). “Lyso-NPs” refers to lysozyme nanoparticels, “ES-(Lyso-NPs)” and 
“ES- (Lyso-NPs-PEG)” refer to electrosprayed-(Lyso-NPs) with and without the modification of 
PEG (Lysozyme: PEG, 1:1, w/w), respectively. The data represent mean ± SD, n= 3， the * indicate 
significant difference for p < 0.05. 
 
3.3 Water contact angle of the EFMs 
 
Hydrophilicity is an important quality attribute for wound dressings as it influences cell viability and 
proliferation rate (42). The images of WCA of all EFMs are showed in Fig. 3. It can be observed that 
the WCA decreased with an increase in the amount of lysozyme in the fibers, which indicates an 
improved hydrophilicity of EFMs. WCA was found to be 126 ± 2º with 1Lyso (1:100, Lyso:PLGA, 
w/w), whereas the addition of 2.5Lyso or 5Lyso(2.5:100 or 5:100, Lyso: PLGA, w/w) resulted in 
WCA of 124 ± 5º and 121 ± 3º, respectively. WCA decreased over time due to water diffusing and 
penetrating into the EFMs. The addition of 10PEG (10:100, PEG:PLGA, w/w) to the EFMs 
decreased the WCA dramatically from 124 ± 5º (2.5Lyso-EFM) to 42 ± 2º, whereas the addition of 








Fig. 3 Water contact angle [º] of Lyso-EFMs with and without the modification of PEG. WCA was 
measured at 0, 30, and 60 min in triplicate, and the images shown are representative for the repeated 
measurements (NA: Not applicable). 
 
3.4 Mechanical properties of EFMs 
 
The mechanical properties of EFMs are important as they are expected to provide physical support 
for wound healing, and the stress-strain curves of EFMs with and without PEG can describe the 
mechanical properties of the produced fibers (Fig. 4). The tensile strength and elongation rate at break 
decreased after adding Lyso-NPs into the EFMs (Fig. 4A). With PEG modification up to the ration 
of 5:100 (PEG:PLGA, w/w), the tensile strength and elongation rate at break were almost 
unchanged. With PEG modification that more than 10:100 (PEG:PLGA, w/w), the tensile strength of 
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EFMs decreased dramatically, however, the elongation rate at break increased (Fig. 4B). The 
similar tendency was observed for Young’s modulus of all the EFMs (Fig. 5). It was found that the 
Young’s modulus decreased with an increase in the amount of Lyso-NPs in the EFMs. However, the 
Young’s modulus was nearly unchanged with the addition of PEG up to 5:100 (PEG:PLGA, w/w) 
of mass ratio, and decreased dramatically with the addition of PEG to more than 10:100 
(PEG:PLGA, w/w). This can possibly be explained by crosslinking of the polymer molecules (PEG 
and PLGA) being disturbed when suspending the Lyso-NPs in the PLGA solution. This tendency 
has previously been observed in a similar study of adding PEG into poly-lactic acid (PLA) 
/poly(butylene succinate) blends (43). As reported in literature, both tensile strength and Young’s 
modulus will decrease with an increase in PEG. This is due to the fact that PEG can act as a 





Fig. 4 Tensile strength of EFMs with and without the addition of PEG. A: Lysozyme loaded PLGA- 






Fig. 5 Young’s modulus of the Lyso-EFMs with and without the modification of PEG (mean ± SD, 
n=3) 
 
It was reported that the Young’s modulus and tensile strength of human skin are around 60-70 MPa 
and 17-21 MPa, respectively (44, 45). In this study, most of the EMFs had a higher Youngs’s modulus 
and comparable tensile strength, compared to human skin, except for the ones with the PEG 
modification more than 10:100 (PEG:PLGA, w/w). Nevertheless, during the wound healing 
process, the initial epithelialization at the injured site, which performed as a temporary protection 
layer is only 15% tensile strength of the original skin (46). Therefore, these EFMs might be able to 
protect the injured site. 
 
3.5 In vitro lysozyme release from the EFMs 
The release of lysozyme from EFMs with PLGA was found to be limited as only 5-25 % lysozyme 
was detected in the medium after 56 days (Fig. 6). An initial drug loading dependent burst release 
can be observed for all the samples within the first 4 h. It might be attributed to the fact that more 
lysozyme accumulate on the surface of fibers during the electrospinning process contributing to the 
fast release. After the burst release, a plateau is present with very slow lysozyme release until the end 
of the release study. The plateau might be explained by the fact that the fibrous mats cannot keep 
their porous structure and began to merge within three weeks in TPBS at 37 ºC (Fig. 7). This 
phenomenon will hinder the release of lysozyme from fibrous mats. After approximately 49 days, the 
fibrous mats began to disintegrate, resulting in a slightly increase of released lysozyme at the last time 
points (Fig. 6A). When comparing the release studies at different temperatures, it can be observed 
that more lysozyme (were) released at RT than at 37 ºC (Fig. 6B). As shown in the SEM images (Fig. 
7), the fibrous mats can keep their integrity after releasing for 56 days with no merging 
phenomenon appeared at RT. The onset of glass transitionof PLGA is around 46 °C 
(Supplementary, Fig. S2 ), close to 37 °C, and therefore the polymer molecules became flexible and 
soft and cannot keep its rigid structure at 37 °C. This can explain the faster degradation at 37 ºC. 
 
The slow and uncompleted drug release behavior is not ideal for successful application in wound 
healing, and therefore, PEG was added to modify the lysozyme release behaviors. For the EFMs with 
PEG modification of 10:100 (PEG:PLGA, w/w), the released lysozyme was found to significantly 
increase from 12.0 ± 3.1% to16.3 ± 1.0 % at 37°C (p-value of 0.04), and at RT the release of 
lysozyme was found to be 24.3 ±1.9 % (Fig. 6B). However, with PEG modification of 20:100 
(PEG:PLGA, w/w), the cumulative release of lysozyme was only 13.2 ± 2.3 % at RT. This can be 
explained by the change of the thermodynamic properties in the physical mixture of PLGA and 
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PEG (47, 48). In literature, it has been reported that adding PEG to PLA resulted in a decrease in Tg 
due to the improved flexibility (47, 49, 50). In this study, with an increase in PEG amount, the 





Fig. 6 Lysozyme release from the EFMs in PBS at pH 7.4. A: at 37 ºC; B: at RT. The data 
represents mean ± SD, n=3. 
 
 
Fig. 7 SEM images of EFMs after the release study at 37 °C for 21 days and at RT for 56 days. 
A: 2.5Lyso-1PEG EFMs and B: 2.5Lyso-5PEG EFMs at 37 °C; C: 2.5Lyso-1PEG EFMs and D: 
2.5Lyso 5PEG EFMs at RT. 
 
For further investigations of the uncompleted drug release, the samples were collected and analyzed 
after 56 days of the release study at RT. For the unreleased lysozyme, only further 13-21% was able 
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to dissolve in the release medium, hence, most of the unreleased lysozyme were insoluble aggregates 
with approximately 46-70 % being physical aggregates (urea soluble) and 0.6-2 % being 
disulfidebonded aggregates (dissolved in urea+ dithiothreitol) (Table 1). The total recovery of 
lysozyme was in the range of 84% to 110% in relation to the total amount of lysozyme loaded into 
EFMs. Therefore, it was found that most lysozyme was not stable and aggregated during the release 
study explaining the poor amount of released lysozyme. 
 
Table 1 Lysozyme stability in PLGA EFMs during the release study over a period of 56 days. 
The data represent mean ± SD, n=3. 










2.5Lyso -1PEG 9 ± 2 13 ± 0.2 70 ± 13 2 ± 1 93 ± 12 
2.5Lyso -5PEG 17 ± 1 20 ± 4 46 ± 5 2 ± 0.7 84 ± 10 
2.5Lyso -10PEG 24 ± 2 16 ± 7 68 ± 11 1 ± 0.7 110 ± 7 
2.5Lyso - 20PEG 13 ± 2 21 ± 4 57 ± 8 0.6 ± 0.6 92 ± 7 
 
3.6 Cytotoxicity of the EFMs 
 
The cytotoxicity of lysozyme loaded EFMs was evaluated using a MTT assay. The samples showed 
negligible cytotoxicity compared to the control group (cell growing in medium) (Fig. 8). Both PLGA 
and PEG are well recognized as safe materials, and are approved by FDA (51, 52) hence, cytotoxicity 
was not expected. No significant differences of the cell viability was observed for the EFMs 
compared to the raw material of PLGA. Therefore, the lysozyme loaded fibrous mats prepared in 




Fig. 8 L929 cell viability assessed by a MTT assay after incubation with PLGA raw materials and 
EFMs for 48 h. Data represent mean ± SD, n=3. 
 
3.7 Cell growth on EFMs 
The morphology of L929 fibroblast cells growing on the Lyso-PEG/PLGA fibrous mats is presented 
in Fig. 9. It can be observed that the cells growing on pure PLGA EFMs were stretched and attached 
along the fibers, whereas the EFMs loaded with lysozyme resulted in round shaped cells and in 
addition they were also stretched across the interconnected fibrous structure. The cells grew on the 
superficial layer of 1Lyso-EFMs, and began to penetrate deeper into the fibrous mats with an 
increase in lysozyme loading (under fibers). The addition of PEG to the EFMs resulted in round 
shaped cells and they also began to penetrate into the fibrous mats with an increase in PEG amount. 
The size of L929 cells used in this study was approximately 10 µm, and it can be observed from the 
SEM images (Fig. 9) that the pore size was much smaller than the cells. The reason why the cells 
can penetrate into the deep layers of the EFMs with much smaller pore size has been interpreted 
previously (53). This cell penetration behavior was explained by the ability of the cells to push aside 
individual fibers in EFMs. If the cells can only grow on the superficial layer and form a tight layer, 





Fig. 9 SEM images of L929 cells growing on EFMs with and without addition of lysozyme and PEG. 




Fig. 10 Morphology of nuclei DNA of L929 cells stained with DAPI after incubation of the cells 
together with EFMs for 48 h. The cells were fixed followed by staining with DAPI, and visualized 
using fluorescence microcopy. 
 
The status of cells that growing on the EFMs was observed using DAPI for staining the cell nuclei 
(Fig. 10). Apoptotic cells were determined by the signs of change of nucleus from round and 
homogenous chromatin to polygonal, detached or sparse, shrinkage, condensed chromatin (54, 55). 
As observed the cells growing on pure PLGA EFMs were dead with a sign of polygonal shape (Fig. 
10), which might because the PLGA EFMs were too hydrophobic for cells to attach. With an 
increase in loaded lysozyme, the cells were less polygonal in shape, and by the addition of PEG, the 
nuclei showed round and homogenous chromatin indicated good cell growth status, especially 
2.5Lyso-5PEG-EFMs and 2.5Lyso -10PEG-EFMs. Both lysozyme and PEG can improve the 
hydrophilicity of EFMs, consequently, improving the affinity between cells and EFMs and 
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facilitating cell attachment and growing. 
4. Conclusion 
 
Lysozyme nanoparticles loaded PLGA EFMs were prepared using electrospray/electrospinning. 
Negligible influence on the bioactivity of lysozyme was observed while being processed using 
‘protein  friendly’  solvents, i.e. binary solvent of EtOH-H2O in this study. Electrospinning is 
demonstrated to be a competitive technique to fabricate biomacromolecules loaded fibrous mats 
with well-retained bioactivity. With an addition of PEG, the hydrophilicity of PLGA EFMs could 
be improved, which facilitated the proliferation of fibroblast cells (L929) on EFMs. The ability of 
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